Search Results
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
achieving stringent complete response (sCR).After infusion of Eque-cel, cytokine release syndrome (CRS) occurred in 11 patients (68.8%), all of which were grade 1-2. The median time to CRS onset was 7 days, with a median duration of 3 days. No neurotoxic effects or immune effector cell-associated
More news about: IASO Bio
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
recoverable.The incidences of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were 64.1% and 6.1%, respectively, all of which were Grade 1-2 and resolved with treatment. Prophylactic use of tocilizumab may reduce incidence, severity, and duration CRS.The incidence of all-grade
More news about: Innovent Biologics
Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
response to VGPR. CT0596 demonstrated a manageable safety profile. Four patients experienced Grade 1 cytokine release syndrome (CRS); no Grade 2 or higher CRS was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) was reported. No dose-limiting
More news about: CARsgen Therapeutics
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
3 or 4 cytokine release syndrome (CRS). According to researchers, this suggests that the combined regimen is safe to administer in a variety of medical settings."There has been some hesitancy to use bispecific antibodies in a community setting because of CRS," said Dr. Falchi. "The prospect of
More news about: American Society of Hematology
Dec 07, 2025, 04:21 ET CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
manageable safety profile and deep, durable efficacy in patients with relapsed/refractory multiple myeloma. No grade 3 or higher cytokine release syndrome (CRS) was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicities, second primary malignancy, or other delayed
More news about: CARsgen Therapeutics
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
life-threatening, occurred following treatment with CARVYKTI®, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with CARVYKTI®. Provide
More news about: Johnson & Johnson
Dec 05, 2025, 12:05 ET MLG CAPITAL'S DAVID RODRIGUEZ HONORED WITH MHN EXCELLENCE AWARD IN THE RISING STAR CATEGORY
FINRA/SIPC. Its Form CRS may be found
More news about: MLG Capital
Dec 04, 2025, 08:10 ET ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions
Clinical Research Solutions (CRS). In this role, Dan will be responsible for leading ProPharma's full-service clinical trials service line.
More news about: ProPharma Group Holdings LLC
Dec 03, 2025, 10:37 ET Land id strikes partnership with Luxury Presence to elevate listing reach with dynamic mapping, geospatial storytelling
positions me as an agent who truly understands properties in Southwest Montana," said Luxury Presence and Land id customer Callie Pecunies, a Broker with CRS, Big Sky Sotheby's International Realty. Land id has worked with a wide-ranging selection of residential agents since inception, partnering with
More news about: Land id, Inc.
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
AEs occurred in 2 (4.1%) patients; one was treatment-related per the investigatorCytokine release syndrome (CRS) of all grades across dose levels was 36.7%CRS all grades was 25.0% at the selected 150 µg/kg dose and 52.4% at the 120 µg/kg dose, with all but one low GradeImmune
More news about: ADC Therapeutics SA
Dec 02, 2025, 09:18 ET Procyrion Appoints Andrew Davis as Chief Commercial Officer
mechanism of action for acute decompensated heart failure (ADHF) patients who remain congested despite standard medical therapy (cardiorenal syndrome or CRS)."I'm honored to join Procyrion to advance the important work already underway," said Mr. Davis. "Patients with diuretic-resistant heart failure
More news about: Procyrion
Dec 02, 2025, 09:00 ET Cowbell Launches Self-Service Platform for Cybersecurity Risk Management Services, Empowering Policyholders with On-Demand Digital Protection
access cybersecurity support. Businesses can now explore available CRS offerings – including managed detection and response, identity monitoring, and cybersecurity awareness training – and request services in just a few clicks.All CRS offerings available through the self-service platform have been
More news about: Cowbell Cyber, Inc.
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
can cause serious side effects, including:Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up
More news about: AbbVie Inc.
Dec 02, 2025, 08:00 ET Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition
with neutropenia, cytokine release syndrome, anemia, and infections as the most common adverse events. All patients experienced Grade ≥3 TEAEs, though CRS events were limited to Grade 1–2 and no tumor lysis syndrome was observed. Preliminary efficacy was encouraging, with ORR of 77.8% and CR rate of 66.7%
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Dec 02, 2025, 04:00 ET Groupe Dubreuil Air Division partners with IBS Software to digitally transform operations and crew management across its airline brands
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Dec 02, 2025, 04:00 ET Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies
More news about: Antengene Corporation Limited
Nov 21, 2025, 07:37 ET Les données de PMB-CT01 BAFFR-CAR T de PeproMene Bio ont été sélectionnées pour deux présentations orales lors de la 67e réunion annuelle de l'ASH 2025.
(HCT) dans un but curatif.Innocuité :Aucune toxicité limitant la dose n'a été observée. Un seul patient a présenté un CRS de grade 2, aucun CRS de grade 3 n'ayant été signalé.« L'activité constante et durable observée à la fois dans la B-ALL et le B-NHL, en particulier chez
More news about: PeproMene Bio, Inc.
Nov 20, 2025, 16:25 ET Daten zu PMB-CT01 BAFFR-CAR T von PeproMene Bio für zwei mündliche Präsentationen auf der 67. Jahrestagung 2025 von ASH ausgewählt
Sicherheit: Es wurden keine dosislimitierenden Toxizitäten (DLTs) beobachtet. Nur bei einem Patienten trat ein CRS des Grades 2 auf, wobei kein CRS des Grades 3 berichtet wurde. „Die konsistente und dauerhafte Aktivität, die sowohl bei B-ALL als auch bei B-NHL
More news about: PeproMene Bio, Inc.
Nov 20, 2025, 14:59 ET ARIZONA@WORK Features JET MX Next-Gen Aviation Mechanic Apprentice Program
Nov. 20, 2025 /PRNewswire/ -- Jet MX, Inc., an FAA-certified aviation maintenance repair station based at Phoenix-Goodyear Airport (FAA 145CRS #JETR229E), operates an aircraft maintenance apprentice program certified by the state of Arizona's Department of Economic Security (DES). DES agency
More news about: JLI Group Holdings, Inc.
Nov 20, 2025, 14:28 ET Confluence Financial Partners Featured on Public Television Documentary All Access with Andy Garcia
investment adviser. Registration of an investment adviser does not imply any level of skill or training. Please refer to our Form ADV Part 2A, Form CRS and the Investment Adviser Public Disclosure (IAPD) website at:
More news about: Confluence Financial Partners
Nov 20, 2025, 10:12 ET PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
Safety: No Dose-Limiting Toxicities (DLTs) were observed. Only one patient experienced Grade 2 CRS, with no Grade 3 CRS reported. "The consistent and durable activity seen across both B-ALL and B-NHL, particularly in patients who have
More news about: PeproMene Bio, Inc.
Nov 20, 2025, 10:12 ET PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
Safety: No Dose-Limiting Toxicities (DLTs) were observed. Only one patient experienced Grade 2 CRS, with no Grade 3 CRS reported. "The consistent and durable activity seen across both B-ALL and B-NHL, particularly in patients who have
More news about: PeproMene Bio, Inc.
Nov 19, 2025, 21:56 ET Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
toward clinical studies for the treatment of autoimmune diseases, can mediate complete B cell depletion with reduced risk of cytokine release syndrome (CRS). ATG-207 (undisclosed bifunctional biologics), is a first-in-class preclinical program being developed for T-cell driven autoimmune diseases.
More news about: Antengene Corporation Limited
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
the 268 patients who experienced CRS, 73% had CRS after the first dose, 60% had CRS after the second dose, and 15% had CRS following the third or later dose. Following the Cycle 1 Day 1, Day 8, Day 15 infusions, 24%, 8%, and 1% of patients experienced Grade ≥ 2 CRS, respectively. From Cycle 2 onwards,
More news about: Amgen
Nov 19, 2025, 13:21 ET MLG CAPITAL WELCOMES KELLY WHETSTONE AS CHIEF COMPLIANCE OFFICER AND ASSOCIATE GENERAL COUNSEL
FINRA/SIPC . Its Form CRS may be found
More news about: MLG Capital